Interaction of cis-diamminedichloroplatinum (II) to chromatin. Specificity of the drug distribution
- PMID: 3768022
- DOI: 10.1016/0006-2952(86)90425-9
Interaction of cis-diamminedichloroplatinum (II) to chromatin. Specificity of the drug distribution
Abstract
We have studied the interaction of the antitumoral drug, cis-diamminedichloroplatinum (II), cis-DDP, to chromatin. Degradation of chromatin-platinum complexes with micrococcal nuclease releases the platinum bound to the linker DNA. By comparing the percentage of platinum released throughout the digestion to the percentage of acid-soluble DNA we suggest that the linker DNA is the preferential target for this drug. This is mainly the case when the amount of bound platinum is low (r less than 0.03) and is less at higher drug concentrations. By comparing the rate constants corresponding to the reaction of cis-DDP to chromatin, DNA or core particle it appears that these constants are the same. This indicates that the bound platinum is located mainly at the DNA level. Our results are discussed with respect to the structure of chromatin and we conclude that this structure should play a role in the in vivo association of cis-DDP to DNA.
Similar articles
-
cis-diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle.Biochim Biophys Acta. 1991 Jul 23;1089(3):377-85. doi: 10.1016/0167-4781(91)90179-p. Biochim Biophys Acta. 1991. PMID: 1859841
-
Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.Cancer Res. 1987 Jan 1;47(1):31-6. Cancer Res. 1987. PMID: 3791217
-
Estimation of the extent of platination and the sites of Pt binding after interaction of cis- and trans-diamminedichloroplatinum(II) with DNA and chromatin.Acta Biochim Pol. 1985;32(2):119-25. Acta Biochim Pol. 1985. PMID: 4041106
-
Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.Met Ions Biol Syst. 1996;33:105-41. Met Ions Biol Syst. 1996. PMID: 8742842 Review.
-
Cisplatin pharmacokinetics: applications of a physiological model.Toxicol Lett. 1988 Oct;43(1-3):117-37. doi: 10.1016/0378-4274(88)90024-0. Toxicol Lett. 1988. PMID: 3051521 Review.
Cited by
-
Differential DNA lesion formation and repair in heterochromatin and euchromatin.Carcinogenesis. 2016 Feb;37(2):129-38. doi: 10.1093/carcin/bgv247. Epub 2015 Dec 30. Carcinogenesis. 2016. PMID: 26717995 Free PMC article.
-
Mechanisms of cellular resistance to cisplatin.Med Oncol Tumor Pharmacother. 1988;5(3):145-51. doi: 10.1007/BF02986437. Med Oncol Tumor Pharmacother. 1988. PMID: 3045443 Review.
-
Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.Cancer Chemother Pharmacol. 1990;26(3):188-92. doi: 10.1007/BF02897197. Cancer Chemother Pharmacol. 1990. PMID: 2357765
-
Reassessing the genotoxic potential of 8-MOP + UVA-induced DNA damage in the yeast Saccharomyces cerevisiae.Curr Genet. 1989 Aug;16(2):75-80. doi: 10.1007/BF00393398. Curr Genet. 1989. PMID: 2688926
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources